NCCN GUIDELINES® INSIGHTS CE Gastrointestinal Stromal Tumors, Version 2.2022 Featured Updates to the NCCN Guidelines: Gastrointestinal Stromal Tumors, Version 2.2022

Margaret von Mehren; John M. Kane; Richard F. Riedel; Jason K. Sicklick; Seth M. Pollack; Mark Agulnik; Marilyn M. Bui; Janai Carr-Ascher; Edwin Choy; Mary Connelly; Sarah Dry; Kristen N. Ganjoo; Ricardo J. Gonzalez; Ashley Holder; Jade Homsi; Vicki Keedy; Ciara M. Kelly; Edward Kim; David Liebner; Martin McCarter; Sean V. McGarry; Nathan W. Mesko; Christian Meyer; Alberto S. Pappo; Amanda M. Parkes; Ivy A. Petersen; Matthew Poppe; Scott Schuetze; Jacob Shabason; Matthew B. Spraker; Melissa Zimel; Mary Anne Bergman; Hema Sundar; Lisa E. Hang

doi:10.6004/jnccn.2022.0058

NCCN GUIDELINES^® INSIGHTS CE Gastrointestinal Stromal Tumors, Version 2.2022 Featured Updates to the NCCN Guidelines: Gastrointestinal Stromal Tumors, Version 2.2022

Margaret von Mehren
, John M. Kane
, Richard F. Riedel
, Jason K. Sicklick
, Seth M. Pollack
, Mark Agulnik
, Marilyn M. Bui
, Janai Carr-Ascher
, Edwin Choy
, Mary Connelly
, Sarah Dry
, Kristen N. Ganjoo
, Ricardo J. Gonzalez
, Ashley Holder
, Jade Homsi
, Vicki Keedy
, Ciara M. Kelly
, Edward Kim
, David Liebner
, Martin McCarter

Sean V. McGarry, Nathan W. Mesko, Christian Meyer, Alberto S. Pappo, Amanda M. Parkes, Ivy A. Petersen, Matthew Poppe, Scott Schuetze, Jacob Shabason, Matthew B. Spraker, Melissa Zimel, Mary Anne Bergman, Hema Sundar, Lisa E. Hang

Roswell Park Comprehensive Cancer Center
Duke University
University of California at San Diego
Northwestern University
City of Hope National Medical Center
University of South Florida
University of California at Davis
Massachusetts General Hospital Cancer Center
Ohio State University
University of California at Los Angeles
Stanford University
University of Alabama at Birmingham
UT Southwestern Simmons Comprehensive Cancer Center
Vanderbilt University
Memorial Sloan-Kettering Cancer Center
Fred Hutchinson Cancer Research Center
University of Colorado Anschutz Medical Campus
University of Nebraska Medical Center
Case Western Reserve University
Johns Hopkins University
University of Tennessee Health Science Center
University of Wisconsin-Madison
Mayo Clinic
University of Utah
University of Michigan, Ann Arbor
University of Pennsylvania
Washington University St. Louis
University of California at San Francisco
National Comprehensive Cancer Network

Research output: Contribution to journal › Article › peer-review

153 Scopus citations

Abstract

Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes. The NCCN Guidelines for GIST provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with these tumors. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised systemic therapy options for unresectable, progressive, or metastatic GIST based on mutational status, and updated recommendations for the management of GIST that develop resistance to specific tyrosine kinase inhibitors.

Original language	English
Pages (from-to)	1204-1214
Number of pages	11
Journal	Journal of the National Comprehensive Cancer Network : JNCCN
Volume	20
Issue number	11
DOIs	https://doi.org/10.6004/jnccn.2022.0058
State	Published - Nov 2022

Keywords

Gastrointestinal Stromal Tumors/diagnosis
Humans
Mutation
Proto-Oncogene Proteins c-kit/genetics
Receptor, Platelet-Derived Growth Factor alpha/genetics

Access to Document

10.6004/jnccn.2022.0058

Cite this

von Mehren, M., Kane, J. M., Riedel, R. F., Sicklick, J. K., Pollack, S. M., Agulnik, M., Bui, M. M., Carr-Ascher, J., Choy, E., Connelly, M., Dry, S., Ganjoo, K. N., Gonzalez, R. J., Holder, A., Homsi, J., Keedy, V., Kelly, C. M., Kim, E., Liebner, D., ... Hang, L. E. (2022). NCCN GUIDELINES^® INSIGHTS CE Gastrointestinal Stromal Tumors, Version 2.2022 Featured Updates to the NCCN Guidelines: Gastrointestinal Stromal Tumors, Version 2.2022. Journal of the National Comprehensive Cancer Network : JNCCN, 20(11), 1204-1214. https://doi.org/10.6004/jnccn.2022.0058

@article{ac24c9a59a88415db5d0881d122f0b98,

title = "NCCN GUIDELINES{\textregistered} INSIGHTS CE Gastrointestinal Stromal Tumors, Version 2.2022 Featured Updates to the NCCN Guidelines: Gastrointestinal Stromal Tumors, Version 2.2022",

abstract = "Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes. The NCCN Guidelines for GIST provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with these tumors. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised systemic therapy options for unresectable, progressive, or metastatic GIST based on mutational status, and updated recommendations for the management of GIST that develop resistance to specific tyrosine kinase inhibitors.",

keywords = "Gastrointestinal Stromal Tumors/diagnosis, Humans, Mutation, Proto-Oncogene Proteins c-kit/genetics, Receptor, Platelet-Derived Growth Factor alpha/genetics",

author = "\{von Mehren\}, Margaret and Kane, \{John M.\} and Riedel, \{Richard F.\} and Sicklick, \{Jason K.\} and Pollack, \{Seth M.\} and Mark Agulnik and Bui, \{Marilyn M.\} and Janai Carr-Ascher and Edwin Choy and Mary Connelly and Sarah Dry and Ganjoo, \{Kristen N.\} and Gonzalez, \{Ricardo J.\} and Ashley Holder and Jade Homsi and Vicki Keedy and Kelly, \{Ciara M.\} and Edward Kim and David Liebner and Martin McCarter and McGarry, \{Sean V.\} and Mesko, \{Nathan W.\} and Christian Meyer and Pappo, \{Alberto S.\} and Parkes, \{Amanda M.\} and Petersen, \{Ivy A.\} and Matthew Poppe and Scott Schuetze and Jacob Shabason and Spraker, \{Matthew B.\} and Melissa Zimel and Bergman, \{Mary Anne\} and Hema Sundar and Hang, \{Lisa E.\}",

note = "Publisher Copyright: {\textcopyright} National Comprehensive Cancer Network, Inc. 2022.",

year = "2022",

month = nov,

doi = "10.6004/jnccn.2022.0058",

language = "English",

volume = "20",

pages = "1204--1214",

journal = "Journal of the National Comprehensive Cancer Network : JNCCN",

issn = "1540-1405",

publisher = "Harborside Press",

number = "11",

}

von Mehren, M, Kane, JM, Riedel, RF, Sicklick, JK, Pollack, SM, Agulnik, M, Bui, MM, Carr-Ascher, J, Choy, E, Connelly, M, Dry, S, Ganjoo, KN, Gonzalez, RJ, Holder, A, Homsi, J, Keedy, V, Kelly, CM, Kim, E, Liebner, D, McCarter, M, McGarry, SV, Mesko, NW, Meyer, C, Pappo, AS, Parkes, AM, Petersen, IA, Poppe, M, Schuetze, S, Shabason, J, Spraker, MB, Zimel, M, Bergman, MA, Sundar, H & Hang, LE 2022, 'NCCN GUIDELINES^® INSIGHTS CE Gastrointestinal Stromal Tumors, Version 2.2022 Featured Updates to the NCCN Guidelines: Gastrointestinal Stromal Tumors, Version 2.2022', Journal of the National Comprehensive Cancer Network : JNCCN, vol. 20, no. 11, pp. 1204-1214. https://doi.org/10.6004/jnccn.2022.0058

NCCN GUIDELINES^® INSIGHTS CE Gastrointestinal Stromal Tumors, Version 2.2022 Featured Updates to the NCCN Guidelines: Gastrointestinal Stromal Tumors, Version 2.2022. / von Mehren, Margaret; Kane, John M.; Riedel, Richard F. et al.
In: Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 20, No. 11, 11.2022, p. 1204-1214.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - NCCN GUIDELINES® INSIGHTS CE Gastrointestinal Stromal Tumors, Version 2.2022 Featured Updates to the NCCN Guidelines

T2 - Gastrointestinal Stromal Tumors, Version 2.2022

AU - von Mehren, Margaret

AU - Kane, John M.

AU - Riedel, Richard F.

AU - Sicklick, Jason K.

AU - Pollack, Seth M.

AU - Agulnik, Mark

AU - Bui, Marilyn M.

AU - Carr-Ascher, Janai

AU - Choy, Edwin

AU - Connelly, Mary

AU - Dry, Sarah

AU - Ganjoo, Kristen N.

AU - Gonzalez, Ricardo J.

AU - Holder, Ashley

AU - Homsi, Jade

AU - Keedy, Vicki

AU - Kelly, Ciara M.

AU - Kim, Edward

AU - Liebner, David

AU - McCarter, Martin

AU - McGarry, Sean V.

AU - Mesko, Nathan W.

AU - Meyer, Christian

AU - Pappo, Alberto S.

AU - Parkes, Amanda M.

AU - Petersen, Ivy A.

AU - Poppe, Matthew

AU - Schuetze, Scott

AU - Shabason, Jacob

AU - Spraker, Matthew B.

AU - Zimel, Melissa

AU - Bergman, Mary Anne

AU - Sundar, Hema

AU - Hang, Lisa E.

PY - 2022/11

Y1 - 2022/11

N2 - Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes. The NCCN Guidelines for GIST provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with these tumors. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised systemic therapy options for unresectable, progressive, or metastatic GIST based on mutational status, and updated recommendations for the management of GIST that develop resistance to specific tyrosine kinase inhibitors.

AB - Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes. The NCCN Guidelines for GIST provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with these tumors. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised systemic therapy options for unresectable, progressive, or metastatic GIST based on mutational status, and updated recommendations for the management of GIST that develop resistance to specific tyrosine kinase inhibitors.

KW - Gastrointestinal Stromal Tumors/diagnosis

KW - Humans

KW - Mutation

KW - Proto-Oncogene Proteins c-kit/genetics

KW - Receptor, Platelet-Derived Growth Factor alpha/genetics

UR - https://www.scopus.com/pages/publications/85141501251

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000898379700006&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.6004/jnccn.2022.0058

DO - 10.6004/jnccn.2022.0058

M3 - Article

C2 - 36351335

SN - 1540-1405

VL - 20

SP - 1204

EP - 1214

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

IS - 11

ER -

NCCN GUIDELINES^® INSIGHTS CE Gastrointestinal Stromal Tumors, Version 2.2022 Featured Updates to the NCCN Guidelines: Gastrointestinal Stromal Tumors, Version 2.2022

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Data on Gastrointestinal Stromal Tumors Discussed by Researchers at Fox Chase Cancer Center (Gastrointestinal Stromal Tumors Version 2.2022 Featured Updates To the Nccn Guidelines)

Cite this

NCCN GUIDELINES® INSIGHTS CE Gastrointestinal Stromal Tumors, Version 2.2022 Featured Updates to the NCCN Guidelines: Gastrointestinal Stromal Tumors, Version 2.2022

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Press/Media

Data on Gastrointestinal Stromal Tumors Discussed by Researchers at Fox Chase Cancer Center (Gastrointestinal Stromal Tumors Version 2.2022 Featured Updates To the Nccn Guidelines)

Cite this

NCCN GUIDELINES^® INSIGHTS CE Gastrointestinal Stromal Tumors, Version 2.2022 Featured Updates to the NCCN Guidelines: Gastrointestinal Stromal Tumors, Version 2.2022